Related Experiment Video

Updated: May 30, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

Denosumab: an update

Cesar E Bogado1, J A Boailchuk, M B Zanchetta

  • 1Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina. bogadoc@idim.com.ar

Drugs of Today (Barcelona, Spain : 1998)
|August 19, 2011
PubMed

Insights

Denosumab, a monoclonal antibody, reduces bone resorption by inhibiting osteoclast activity. Clinical studies show it effectively decreases fracture risk in postmenopausal osteoporosis and prostate cancer patients.

Area of Science:

  • Pharmacology
  • Immunology
  • Bone Biology

Background:

  • Osteoclasts are crucial for bone resorption.
  • Dysregulation of osteoclast activity leads to bone diseases like osteoporosis.
  • Denosumab targets key pathways regulating osteoclastogenesis.

Purpose of the Study:

  • To evaluate denosumab's efficacy and safety in preventing fractures.
  • To assess denosumab's impact on bone mineral density.
  • To explore denosumab's potential in various bone loss conditions.

Main Methods:

  • Denosumab is a fully human monoclonal antibody.
  • It inhibits the RANKL/RANK signaling pathway.
  • Clinical trials assessed fracture incidence, bone mineral density, and safety profiles.

Main Results:

  • Denosumab significantly reduced vertebral, hip, and nonvertebral fractures in postmenopausal osteoporosis.
  • It decreased the risk of new vertebral fractures in men with prostate cancer on androgen deprivation therapy.
  • Side effect rates were comparable to placebo.

Conclusions:

  • Denosumab is an effective treatment for postmenopausal osteoporosis, reducing fracture risk.
  • It offers a new therapeutic option for men with prostate cancer at risk of skeletal complications.
  • Ongoing trials are investigating broader applications and immunomodulatory effects.

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...